319 related articles for article (PubMed ID: 16368879)
21. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
23. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
24. EAE tolerance induction with Hsp70-peptide complexes depends on H60 and NKG2D activity.
Galazka G; Jurewicz A; Orlowski W; Stasiolek M; Brosnan CF; Raine CS; Selmaj K
J Immunol; 2007 Oct; 179(7):4503-12. PubMed ID: 17878346
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
[TBL] [Abstract][Full Text] [Related]
26. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
27. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
28. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
29. NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors.
Regunathan J; Chen Y; Wang D; Malarkannan S
Blood; 2005 Jan; 105(1):233-40. PubMed ID: 15328154
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.
Charalambous A; Oks M; Nchinda G; Yamazaki S; Steinman RM
J Immunol; 2006 Dec; 177(12):8410-21. PubMed ID: 17142738
[TBL] [Abstract][Full Text] [Related]
31. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
[TBL] [Abstract][Full Text] [Related]
32. The ischemia-responsive protein 94 (Irp94) activates dendritic cells through NK cell receptor protein-2/NK group 2 member D (NKR-P2/NKG2D) leading to their maturation.
Srivastava RM; Varalakshmi C; Khar A
J Immunol; 2008 Jan; 180(2):1117-30. PubMed ID: 18178852
[TBL] [Abstract][Full Text] [Related]
33. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer.
Lee SH; Mizutani N; Mizutani M; Luo Y; Zhou H; Kaplan C; Kim SW; Xiang R; Reisfeld RA
Cancer Immunol Immunother; 2006 Dec; 55(12):1565-74. PubMed ID: 16565828
[TBL] [Abstract][Full Text] [Related]
34. NK cells are primed by ANRS MVA(HIV)-infected DCs, via a mechanism involving NKG2D and membrane-bound IL-15, to control HIV-1 infection in CD4+ T cells.
Moreno-Nieves UY; Didier C; Lévy Y; Barré-Sinoussi F; Scott-Algara D;
Eur J Immunol; 2014 Aug; 44(8):2370-9. PubMed ID: 24777763
[TBL] [Abstract][Full Text] [Related]
35. Costimulation of multiple NK cell activation receptors by NKG2D.
Ho EL; Carayannopoulos LN; Poursine-Laurent J; Kinder J; Plougastel B; Smith HR; Yokoyama WM
J Immunol; 2002 Oct; 169(7):3667-75. PubMed ID: 12244159
[TBL] [Abstract][Full Text] [Related]
36. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
[TBL] [Abstract][Full Text] [Related]
37. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
39. Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide.
Choi EY; Christianson GJ; Yoshimura Y; Sproule TJ; Jung N; Joyce S; Roopenian DC
Immunity; 2002 Nov; 17(5):593-603. PubMed ID: 12433366
[TBL] [Abstract][Full Text] [Related]
40. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.
Jinushi M; Hodi FS; Dranoff G
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9190-5. PubMed ID: 16754847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
